Scientists Use Gene-Editing to Tackle High Cholesterol with Promising Results
Scientists are employing CRISPR-Cas9 technology to permanently deactivate two liver genes, PCSK9 and angiopoietin-like protein 3, which are common targets for lowering LDL cholesterol levels. Recent small clinical trials have shown promising results, with the gene-editing approach potentially offering a 'one and done' treatment. The trials demonstrated significant reductions in cholesterol levels, with the PCSK9 gene editing lowering cholesterol by 62% and angiopoietin-like protein 3 by nearly 50%. This innovative method could eliminate the need for daily cholesterol-lowering medications, marking a significant advancement in medical treatment for high cholesterol. 
